Cutaneous sensitivity modulation by Aquaphilus dolomiae extract‐G3 on in vitro models of neuro‐inflammation. (1st September 2020)

• Record Type: Journal Article
• Authors: Lestienne, F.; Viodé, C.; Ceruti, I.; Carrere, S.; Bessou‐Touya, S.; Duplan, H.; Castex‐Rizzi, N.
• Is Part Of: Journal of the European Academy of Dermatology and Venereology. Volume 34(2020)Supplement 5
• Page Start: 43
• Page End: 48
• Publication Date: 2020-09-01
• Subjects: Dermatology -- Periodicals; Sexually transmitted diseases -- Periodicals; 616.5
• DOI: 10.1111/jdv.16641
• Languages: English
• ISSNs: 0926-9959

Abstract

Abstract: Background: Inflammatory skin disorders, including atopic dermatitis (AD), associated pruritus and sensitive skin, have a complex multifactorial pathogenesis including neurogenic inflammation involving the release in blood and skin of neurotransmitters such as substance P (SP). Aims and Methods: In vitro models evaluated the effect of the original biological extract of Aquaphilus dolomiae extract‐G3 (ADE‐G3) on cutaneous neurogenic inflammation. Results: ADE‐G3 significantly inhibited SP‐stimulated release of IL‐1β and TNF‐α from normal human epidermal keratinocytes; significantly and dose‐dependently inhibited SP‐stimulated activation of human mast cells; significantly inhibited veratridine‐stimulated release of SP from human sensory neurons; modulated expression of genes involved in lipid synthesis, innate immunity, corneocyte scaffolding and epidermal differentiation in a histamine‐sensitized reconstructed human epidermis model; and, when applied topically to ex vivo human explants, inhibited IL‐8 and histamine release. Conclusions: Topically applied ADE‐G3, once formulated, may improve neuro‐inflammation in patients with inflammatory skin disorders.